-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

Benzinga·12/05/2025 17:29:43
Listen to the news
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.